Histamine & MS: Real Science, Real Studies

Peer-reviewed articles, trials, and research that connect the dots between histamine and multiple sclerosis.

Elevated CSF Histamine Levels in Multiple Sclerosis Patients
(Kallweit et al., Fluids and Barriers of the CNS, 2013)

Repurposing Histaminergic Drugs in Multiple Sclerosis
(Amadio et al., International Journal of Molecular Sciences, 2022)

The Histamine and Multiple Sclerosis Alliance: Pleiotropic Actions and Functional Validation
(Volonté et al., Current Topics in Behavioral Neurosciences, 2021)

Clemastine fumarate as a remyelinating therapy for multiple sclerosis (ReBUILD)
(UCSF clinical trial registry describing ReBUILD methodology and outcomes)

Transdermal Histamine in Multiple Sclerosis: Clinical Experience at Tahoma Clinic
(Gillson et al., Alternative Medicine Review, 1999)

Histamine and Histamine Receptors in Pathogenesis and Treatment of Multiple Sclerosis
(Neuropharmacology, 2010)

Possible role of histamine in pathogenesis of autoimmune diseases: implications for immunotherapy with histamine-2 receptor antagonists

Evidence for the involvement of histamine in the regulation of blood-brain barrier permeability
(Pharmacol Res Commun.)

Targeting the muscarinic M1 receptor with a selective, brain-penetrant antagonist to promote remyelination in multiple sclerosis
(PNAS, 2024)